<DOC>
	<DOCNO>NCT01585584</DOCNO>
	<brief_summary>The purpose study test potential antiviral efficacy triple-combination therapy Peginterferon α-2b + ribavirin + boceprevir ( PRB ) patient HCV genotype 3 previously fail Peginterferon α + ribavirin ( non-responders relapsers ) .</brief_summary>
	<brief_title>Triple-Therapy Patients With HCV Genotype 3 Who Previously Failed Treatment</brief_title>
	<detailed_description>) Obtain preliminary information association important baseline on-treatment factor SVR patient population . Variables examine may include gender , age , advanced fibrosis cirrhosis ( F3 F4 estimate Fibroscan ) , baseline viral load , RVR , wk 8 viral load , end-of-treatment viral response . ii ) Evaluate adverse event . iii ) Evaluate viral resistance .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Subjects eligible study meet follow inclusion criterion : 1 . 18 year age old 2 . Infected HCV genotype 3 ( mixed genotype NOT permit ) 3 . Have receive least 12 week previous treatment peginterferonα + ribavirin 4 . Detectable serum HCVRNA 5 . No significant comorbid condition 6 . Liver biopsy necessary 7 . Cirrhotic patient eligible participate ChildPugh class A ( maximum 15 % subject ) Subjects excluded participation study follow condition present : 1 . Significant comorbidities : uncontrolled psychiatric condition include severe depression , cardiovascular , respiratory , renal metabolic condition , active carcinoma . 2 . Active substance abuse within past 12 month 3 . Coinfection hepatitis B HIV 4 . Decompensated cirrhosis ( ChildPugh class B C ) 5 . Significant cytopenia follow : platelet &lt; 80 x 109/L , neutropenia &lt; 1.2 x 103/L , Hb &lt; 120 g/l men 110 g/l woman 6 . Lack inform consent 7 . Previous nullresponders ( &lt; 2 log10 decrease week 12 previous PR therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Boceprevir</keyword>
	<keyword>Hepatitis C Genotype 3</keyword>
</DOC>